tirzepatide and lithium Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply access for adults living with obesity Eli Lilly's Tirzepatide Shows Promise

Retatrutide is an investigational medication that is not approved by the FDA or any major regulatory body as of February 2026

Scientific Reports 5, 1-11

XTALKS WEBINAR: Sarcopenia: Changes and Challenges in Body Composition with GLP-1 Receptor Agonist-based Weight Loss Therapies Live and On-Demand: Friday, September 6, 2024 , at 10am EDT (4pm CEST / EU-Central) Register for this free webinar to learn about the latest clinical trial data on GLP-1 receptor agonist-based therapies and their impact on weight loss and body composition

Step 1: Get Matched With a Licensed Provider Begin by completing a short form

The process of tirzepatide dose escalation A structured dose-escalation schedule helps many patients balance tolerability with ongoing progress